Skip to main content

Table 1 Baseline measurements

From: Cardioprotective effects of enteral vs. parenteral lactoferrin administration on myocardial ischemia-reperfusion injury in a rat model of stunned myocardium

A. Enteral administration groups

 

Control

E-LF 7.5m

E-LF 15m

E-LF 30m

E-LF 60m

Number (n)

8

8

8

8

8

LV dP/dt max (mmHg/s)

2500 ± 213

2556 ± 253

2608 ± 271

2669 ± 321

2391 ± 147

Heart rate (bpm)

236 ± 25

234 ± 24

226 ± 21

244 ± 18

255 ± 42

Coronary flow (mL/min)

14.1 ± 1.3

13.3 ± 0.7

14.4 ± 0.9

14.0 ± 1.7

13.0 ± 1.5

B. Parenteral administration groups

 

Control

P-LF 15

P-LF 100

Number (n)

8

8

8

LV dP/dt max (mmHg/s)

2583 ± 374

2546 ± 420

2569 ± 289

Heart rate (bpm)

270 ± 42

256 ± 52

246 ± 29

Coronary flow (mL/min)

15.7 ± 1.8

14.4 ± 0.9

14.7 ± 1.7

  1. Data are presented as mean ± standard deviation.
  2. E-LF: enteral lactoferrin, LV dP/dt max: maximum left ventricular derivative of pressure development, P-LF: perfusate lactoferrin.